Kısa Bildiri
BibTex RIS Kaynak Göster

Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2

Yıl 2020, Cilt: 2 Sayı: 1, 27 - 29, 23.04.2020

Mehmet Çıtırık

Öz

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated first case was reported in December 2019 and spread rapidly all over the world. During this period, it is emphasized that the special requirements for any ophthalmological examination should be fulfilled. An important issue for retina clinics is the intravitreal injection application. Procrastination is possible in all intravitreal injections (anti-VEGF, steroid), and a 2-3-month delay may not be a major problem for some diagnoses. However, in some patients, the result of delayed injection may be more severe. Additionally, for procedures requiring physical proximity, such as intravitreal injections and emergency surgeries, it is important to take additional precautions for COVID-19. Another issue is the use of hydroxychloroquine and chloroquine during the COVID-19 outbreak. The toxic cumulative drug dose of drugs is much more than the recommended dose for COVID-19.

Anahtar Kelimeler

Retina Pandemi Coronavirus SARS-CoV-2 COVID-19

Destekleyen Kurum

None

Proje Numarası

None

Teşekkür

None

Kaynakça

  • 1. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Last viewed 21 April, 2020.
  • 2. Coronavirus Disease 2019 (COVID-19), Prevent Getting Sick, How to Protect Yourself & Others. https://www.cdc.gov/coronavirus/ 2019-ncov/prevent-getting-sick/prevention.html, Last viewed 21 April, 2020.
  • 3. Minocha A, Sim SY, Than J, Vakros G. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals. Eye (Lond). 2020 Apr 7.
  • 4. American Academy of Ophthalmology web site. Important coronavirus updates for ophthalmologists . https://www. aao.org/headline/alert-important-coronavirus-context (Last viewed 21 April, 2020.)
  • 5. Turkish Republic Ministry of Health. Scientific Commission Study. COVID-19 Guide. https://covid19bilgi.saglik.gov.tr/ depo/rehberler/COVID-19_Rehberi.pdf (Last viewed 21 April, 2020.)
  • 6.Sulman S. Hydroxychloroquine Maculopathy: An Update on Screening and Diagnosis. Retinal Physician. 2015; 12 (November 2015): 70-72.
  • 7. Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO). https://clinicaltrials.gov/ ct2/show/NCT04120883. Last viewed 21 April, 2020.
  • 8. Chin MS, Hooper LC, Hooks JJ, Detrick B. Identification of α-fodrin as an autoantigen in experimental coronavirus retinopathy (ECOR). J Neuroimmunol. 2014; 272(1-2): 42-50.

Yıl 2020, Cilt: 2 Sayı: 1, 27 - 29, 23.04.2020

Mehmet Çıtırık

Öz

Proje Numarası

None

Kaynakça

  • 1. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Last viewed 21 April, 2020.
  • 2. Coronavirus Disease 2019 (COVID-19), Prevent Getting Sick, How to Protect Yourself & Others. https://www.cdc.gov/coronavirus/ 2019-ncov/prevent-getting-sick/prevention.html, Last viewed 21 April, 2020.
  • 3. Minocha A, Sim SY, Than J, Vakros G. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals. Eye (Lond). 2020 Apr 7.
  • 4. American Academy of Ophthalmology web site. Important coronavirus updates for ophthalmologists . https://www. aao.org/headline/alert-important-coronavirus-context (Last viewed 21 April, 2020.)
  • 5. Turkish Republic Ministry of Health. Scientific Commission Study. COVID-19 Guide. https://covid19bilgi.saglik.gov.tr/ depo/rehberler/COVID-19_Rehberi.pdf (Last viewed 21 April, 2020.)
  • 6.Sulman S. Hydroxychloroquine Maculopathy: An Update on Screening and Diagnosis. Retinal Physician. 2015; 12 (November 2015): 70-72.
  • 7. Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO). https://clinicaltrials.gov/ ct2/show/NCT04120883. Last viewed 21 April, 2020.
  • 8. Chin MS, Hooper LC, Hooks JJ, Detrick B. Identification of α-fodrin as an autoantigen in experimental coronavirus retinopathy (ECOR). J Neuroimmunol. 2014; 272(1-2): 42-50.
Toplam 8 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Göz Hastalıkları
Bölüm Short Communication
Yazarlar

Mehmet Çıtırık

Proje Numarası None
Yayımlanma Tarihi 23 Nisan 2020
Kabul Tarihi 27 Nisan 2020
Yayımlandığı Sayı Yıl 2020 Cilt: 2 Sayı: 1

Kaynak Göster

APA Çıtırık, M. (2020). Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. Clinical and Experimental Ocular Trauma and Infection, 2(1), 27-29.
AMA Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. Nisan 2020;2(1):27-29.
Chicago Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection 2, sy. 1 (Nisan 2020): 27-29.
EndNote Çıtırık M (01 Nisan 2020) Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. Clinical and Experimental Ocular Trauma and Infection 2 1 27–29.
IEEE M. Çıtırık, “Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2”, CEOTI, c. 2, sy. 1, ss. 27–29, 2020.
ISNAD Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection 2/1 (Nisan 2020), 27-29.
JAMA Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. 2020;2:27–29.
MLA Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection, c. 2, sy. 1, 2020, ss. 27-29.
Vancouver Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. 2020;2(1):27-9.
 Kapak Resmi İndir

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(CC BY-NC-SA 4.0)